Cynata Therapeutics Limited (CYYNF)
OTC GREY OTC GREY Primary 
Cynata Therapeutics Limited (CYYNF) Discusses Clinical Trial Progress and Corporate Developments Including GVHD, Osteoarthritis, and Kidney Transplantation Transcript
Cynata Therapeutics Limited (OTCPK:CYYNF) Discusses Clinical Trial Progress and Corporate Developments Including GVHD, Osteoarthritis, and Kidney Transplantation November 5, 2025 8:30 PM EST Company Participants Lauren Nowak Kilian Kelly - MD, CEO & Director Mathias Kroll - Chief Business Officer Presentation Lauren Nowak All right, seems like everybody has managed to make their way. So I just wanted to say good morning, and thank you for joining Cynata Therapeutics Investor Webinar for the September 2025 quarter.
Cynata Therapeutics Limited (CYYNF) Q4 2025 Earnings Call Transcript
Cynata Therapeutics Limited (OTCPK:CYYNF) Q4 2025 Earnings Conference Call August 4, 2025 9:00 PM ET Company Participants Kilian Kelly - MD, CEO & Director Mathias Kroll - Chief Business Officer Kilian Kelly [Starts Abruptly] for now, just to explain that we will go through a fairly brief presentation, just to summarize the key highlights of the recently completed quarter. And following that, we'll have a Q&A session.
Cynata Therapeutics Limited (CYYNF) Investor Webinar Transcript
Cynata Therapeutics Limited (OTCPK:CYYNF) Investor Webinar Conference Call February 5, 2025 6:30 PM ET Company Participants Lauren Nowak - Media Relations Kilian Kelly - Chief Executive Officer and Managing Director Mathias Kroll - Chief Business Officer Geoff Brooke - Independent Non-Executive Chairman Conference Call Participants Lauren Nowak Okay. Great. Let's get going.
